Cornea research pioneer honored with Champalimaud Vision AwardSeptember 16th 2022
Claes H. Dohlman, MD, PhD, widely considered the father of modern cornea science, is a recipient of the 2022 António Champalimaud Vision Award. The award, considered the “Nobel Prize of Vision," comes with a $1 million prize .
Presbyopia-correcting IOL receives high marksAugust 26th 2022
The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches.
Oyster Point Pharma announces varenicline solution nasal spray for treatment of dry eye to be covered by key Medicare pharmacy benefit managerAugust 17th 2022
Oyster Point Pharma Inc. today announced that the largest Medicare pharmacy benefit manager in the United States will add its varenicline solution nasal spray (Tyrvaya) for the treatment of dry eye on its Medicare Part D formularies, effective September 1.
Elkin: Talking about the importance of pediatric eye health and safetyAugust 10th 2022
Zachary Elkin, MD, MPH, of NYU Langone Eye Center, advises how ophthalmologists and parents should be aware of precautions that should be taken with sports involving small balls and urges the use of protective eyewear.
Oyster Point Pharma announces expanded patient access to varenicline solutionJuly 28th 2022
Oyster Point Pharma Inc. this week announced the expansion of patient access to varenicline solution (Tyrvaya) nasal spray and provided an update on the commercial performance of the spray in the United States. According to the company, its expanded patient access programs include more eligible patients with dry eye disease.
FDA approves the AcuFocus IC-8 small aperture IOL for cataract surgeryJuly 25th 2022
Results from the U.S. pivotal trial showed Apthera IOL subjects achieved statistically superior uncorrected intermediate and near vision, and equivalent distance vision and contrast sensitivity compared to control subjects.
Carl Zeiss Meditec, Precise Bio announce partnership in the development and commercialization of tissue-based implants for ophthalmologyJuly 20th 2022
The companies will jointly develop 4D bio-fabricated corneal transplants for diseases that require endothelial keratoplasty and natural lenticule transplants.
RegeneRx partner signs LOI with global ophthalmology CRO for Phase 3 clinical trials in neurotrophic keratitisJuly 19th 2022
The company and its U.S. joint venture partner and licensee, HLB Therapeutics, signed a letter of intent this week with a global ophthalmology contract research organization to conduct a pair of phase 3 clinical trials simultaneously beginning in the fall in the U.S. and Europe for patients with neurotrophic keratitis.
Study: Assaults with paintball guns cause more serious eye injuries than previously knownJuly 19th 2022
University of Chicago Medical Center investigators reviewed 2 years of data on assaults with paintball guns found more patients than expected suffered vision-threatening emergencies after being struck in the eye, with several experiencing a rupture of the eyeball or even permanent blindness.
Research to Prevent Blindness awards grant to OU Department of OphthalmologyJuly 12th 2022
The University of Oklahoma Health Sciences Center has received an unrestricted grant from Research to Prevent Blindness for $575,000 over 5 years to support eye research conducted by the Department of Ophthalmology.
Kala Pharmaceuticals completes sale of Eysuvis, Inveltys to Alcon Inc.July 11th 2022
Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May.